Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

COUCH Medcomms

How does Genesis Research Group ‘Innovate differently’?

New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...

Genesis Research Group

- PMLiVE

Mtech Access have joined Petauri!

Mtech Access are now part of Petauri. This marks a significant and exciting milestone in our journey, and aligns with our commitment to partnering with industry to bring life-enhancing technologies...

Petauri Evidence

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

world epa vaccines

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...

Genesis Research Group

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...

Genesis Research Group

- PMLiVE

AstraZeneca’s Calquence shows survival benefit in phase 3 mantle cell lymphoma study

The rare form of non-Hodgkin lymphoma is estimated to affect more than 27,500 people globally

- PMLiVE

Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer

Approximately 67,880 new cases of uterine cancer will be diagnosed in the US this year

- PMLiVE

Roche announces positive phase 3 results for Columvi combination in DLBCL

The most common form of non-Hodgkin lymphoma affects 160,000 people worldwide every year

- PMLiVE

Takeda shares late-stage results for investigational soticlestat in rare epileptic disorders

Dravet syndrome and Lennox-Gastaut syndrome are drug-resistant to many anti-seizure medications

- PMLiVE

PM Society’s charity partner announced as Acrodysostosis Support and Research

Creativity for Good is part of the PM Society’s giving back initiative

- PMLiVE

Spotting creative opportunities is like spotting yellow cars

By Dick Dunford

- PMLiVE

Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication

More than 6,500 new cases of the blood cancer were diagnosed in the US last year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links